Clinical Research
Acute Ischemia or Infarction
Coagulopathy After Successful Cardiopulmonary Resuscitation Following Cardiac Arrest: Implication of the Protein C Anticoagulant Pathway

https://doi.org/10.1016/j.jacc.2005.03.046Get rights and content
Under an Elsevier user license
open archive

Objectives

We investigated coagulation abnormalities in out-of-hospital cardiac arrest (OHCA) patients, with special attention to the protein C anticoagulant pathway.

Background

Successfully resuscitated cardiac arrest is followed by a systemic inflammatory response and by activation of coagulation, both of which may contribute to organ failure and neurological dysfunction.

Methods

Coagulation parameters were measured in all patients admitted after successfully resuscitated OHCA.

Results

At admission, 67 patients had a systemic inflammatory response with increased interleukin-6 and coagulation activity (thrombin-antithrombin complex), reduced anticoagulation (antithrombin, protein C, and protein S), activated fibrinolysis (plasmin-antiplasmin complex), and, in some cases, inhibited fibrinolysis (increased plasminogen activator inhibitor-1 with a peak on day 1). These abnormalities were more severe in patients who died within two days (50 of 67, 75%) and were most severe in patients dying from early refractory shock. Protein C and S levels were low compared to healthy volunteers and discriminated OHCA survivors from nonsurvivors. Furthermore, a subgroup of patients had a transient increase in plasma-activated protein C at admission followed by undetectable levels. This, along with an increase in soluble thrombomodulin over time, suggests secondary endothelial injury and dysfunction of the protein C anticoagulant pathway similar to that observed in severe sepsis.

Conclusions

Major coagulation abnormalities were found after successful resuscitation of cardiac arrest. These abnormalities are consistent with secondary down-regulation of the thrombomodulin-endothelial protein C receptor pathway.

Abbreviations and Acronyms

AT
antithrombin
CPR
cardiopulmonary resuscitation
ICU
intensive care unit
IL
interleukin
LOD
Logistic Organ Dysfunction score
OHCA
out-of-hospital cardiac arrest
PAI
plasminogen activator inhibitor
PAP
plasmin-antiplasmin complex
SAPS II
Simplified Acute Physiology score
sTM
soluble thrombomodulin
TAT
thrombin-antithrombin complex

Cited by (0)

Suzan Um and Dr. Yan are employees of Eli Lilly and Company, and Dr. Dhainaut has served as a consultant for Eli Lilly and Company. However, this study was a research collaboration effort and was not funded by Lilly.